TCGA-GC-A4ZW-01A-11R-A26T-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.492772668
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.560
- G2M_CHECKPOINT+0.450
- MYC_TARGETS_V1+0.420
- DNA_REPAIR+0.400
- MYC_TARGETS_V2+0.390
- MITOTIC_SPINDLE+0.360
- PROTEIN_SECRETION+0.360
- UNFOLDED_PROTEIN_RESPONSE+0.340
- OXIDATIVE_PHOSPHORYLATION+0.280
- HEME_METABOLISM+0.240
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.580
- ANGIOGENESIS-0.550
- INFLAMMATORY_RESPONSE-0.470
- INTERFERON_ALPHA_RESPONSE-0.450
- COAGULATION-0.420
- ALLOGRAFT_REJECTION-0.410
- IL6_JAK_STAT3_SIGNALING-0.410
- INTERFERON_GAMMA_RESPONSE-0.400
- APICAL_SURFACE-0.360
- KRAS_SIGNALING_UP-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-DK-A3X2-01A-11R-A22U-07 | — | — | 0.936 |
| 2 | MDT-AP-3402 | Med | Medulloblastoma | 0.926 |
| 3 | MDT-AP-0714 | Med | Medulloblastoma | 0.922 |
| 4 | TCGA-HQ-A2OE-01A-11R-A206-07 | — | — | 0.915 |
| 5 | TCGA-C8-A1HN-01A-11R-A137-07 | — | B | 0.909 |
| 6 | MBCproject_0227_T2_RNA | — | B | 0.907 |
| 7 | 004064de-0e10-491d-b3d8-bc628a8f70a8 | — | — | 0.905 |
| 8 | 236350e9-8964-42ae-8880-d2f2281ff993 | — | — | 0.898 |
| 9 | a8ce7460-8ccd-4638-a854-55c4068af6ec | — | — | 0.897 |
| 10 | MDT-AP-2085 | Med | Medulloblastoma | 0.897 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.560 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.450 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.420 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.400 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.390 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.360 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.360 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.340 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.280 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.240 | Temsirolimus | — uncovered |
| ANDROGEN_RESPONSE | 0.210 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.210 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| PEROXISOME | 0.160 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.160 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.160 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.140 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.090 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.060 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.040 | Idelalisib | — uncovered |